SK9852001A3 - Triazole compounds with dopamine-d3-receptor affinity - Google Patents

Triazole compounds with dopamine-d3-receptor affinity Download PDF

Info

Publication number
SK9852001A3
SK9852001A3 SK985-2001A SK9852001A SK9852001A3 SK 9852001 A3 SK9852001 A3 SK 9852001A3 SK 9852001 A SK9852001 A SK 9852001A SK 9852001 A3 SK9852001 A3 SK 9852001A3
Authority
SK
Slovakia
Prior art keywords
phenyl
alkyl
methyl
ylsulfonyl
triazol
Prior art date
Application number
SK985-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Dorothea Starck
Hans-Jorg Treiber
Liliane Unger
Barbara Neumann-Schultz
Kai Blumbach
Dietmar Schobel
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of SK9852001A3 publication Critical patent/SK9852001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK985-2001A 1999-01-12 2000-01-12 Triazole compounds with dopamine-d3-receptor affinity SK9852001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19900811 1999-01-12
PCT/EP2000/000177 WO2000042036A1 (fr) 1999-01-12 2000-01-12 Composes de triazol presentant une affinite pour le recepteur 3 de la dopamine

Publications (1)

Publication Number Publication Date
SK9852001A3 true SK9852001A3 (en) 2002-04-04

Family

ID=7894006

Family Applications (2)

Application Number Title Priority Date Filing Date
SK986-2001A SK9862001A3 (en) 1999-01-12 2000-01-12 Triazole compounds with dopamine-d3-receptor affinity
SK985-2001A SK9852001A3 (en) 1999-01-12 2000-01-12 Triazole compounds with dopamine-d3-receptor affinity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK986-2001A SK9862001A3 (en) 1999-01-12 2000-01-12 Triazole compounds with dopamine-d3-receptor affinity

Country Status (28)

Country Link
US (3) US6602867B1 (fr)
EP (3) EP1144405B1 (fr)
JP (3) JP4615125B2 (fr)
KR (3) KR100687682B1 (fr)
CN (3) CN1149209C (fr)
AR (3) AR022228A1 (fr)
AT (3) ATE366729T1 (fr)
AU (3) AU773047B2 (fr)
BG (2) BG65105B1 (fr)
BR (2) BR0007500A (fr)
CA (3) CA2359952A1 (fr)
CO (3) CO5150227A1 (fr)
CZ (2) CZ20012550A3 (fr)
DE (3) DE50015576D1 (fr)
ES (2) ES2334326T3 (fr)
HK (1) HK1045311B (fr)
HR (1) HRP20010590A2 (fr)
HU (2) HUP0200522A3 (fr)
ID (2) ID29930A (fr)
IL (3) IL144137A0 (fr)
NO (2) NO20013443L (fr)
NZ (2) NZ512864A (fr)
PL (2) PL201889B1 (fr)
SK (2) SK9862001A3 (fr)
TR (2) TR200102025T2 (fr)
TW (1) TWI274750B (fr)
WO (3) WO2000042037A1 (fr)
ZA (2) ZA200106584B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
ES2255311T3 (es) 1998-10-08 2006-06-16 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina utiles como moduladores de los receptores d3 de dopamina (agentes anti-psicoticos).
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
US7229986B2 (en) * 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
CA2428844A1 (fr) * 2000-11-14 2002-05-23 Michael Stewart Hadley Derives de tetrahydrobenzazepine utiles en tant que modulateurs des recepteurs d3 de la dopamine (agents antipsychotiques)
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20050176759A1 (en) * 2001-12-21 2005-08-11 Mahmood Ahmed 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
AR040126A1 (es) 2002-05-29 2005-03-16 Glaxo Group Ltd Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
DE10304870A1 (de) * 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
ATE397755T1 (de) * 2003-03-17 2008-06-15 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2005051945A1 (fr) * 2003-11-20 2005-06-09 Eli Lilly And Company Composes heterocycliques utilises comme modulateurs des recepteurs actives proliferateurs du peroxysome (ppar), utiles dans le traitement et/ou la prevention de troubles modules par un ppar
KR20050054084A (ko) * 2003-12-03 2005-06-10 한국전자통신연구원 수신 환경에 기반한 위성 상태 데이터 분배 기능을 가지는위성관제 시스템 및 그 방법
AR047890A1 (es) 2004-02-23 2006-03-01 Glaxo Group Ltd Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
WO2005087764A1 (fr) * 2004-03-08 2005-09-22 Glaxo Group Limited Derives de tetrahydrobenzazepine comme modulateurs de recepteurs d3 de la dopamine (agents antipsychotiques)
WO2005090320A2 (fr) * 2004-03-12 2005-09-29 Wyeth Derives de triazole et leur methode d'utilisation pour traiter les infections par le vih
GB0412314D0 (en) * 2004-06-02 2004-07-07 Glaxo Group Ltd Compounds
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
GB0413879D0 (en) 2004-06-21 2004-07-21 Glaxo Group Ltd Compounds
GB0414795D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
EP1778684B1 (fr) 2004-08-09 2009-12-16 Abbott GmbH & Co. KG COMPOSÉS DE 4-PIPÉRAZINYLPYRIMIDINE CONVENANT POUR TRAITER DES TROUBLES QUI RÉPONDENT À UNE MODULATION DU RÉCEPTEUR D<sb>3</sb> DE LA DOPAMINE
US7572783B2 (en) * 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
JP5049134B2 (ja) 2004-12-02 2012-10-17 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンｄ３受容体の調節に応答する障害の治療に好適なトリアゾール化合物
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
WO2006133945A1 (fr) * 2005-06-14 2006-12-21 Glaxo Group Limited Nouveaux composés
TWI446910B (zh) 2005-08-18 2014-08-01 Synta Pharmaceuticals Corp 調節ｈｓｐ９０活性的三唑化合物
US7799815B2 (en) 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
WO2007028145A2 (fr) * 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents et procede permettant de reduire l'activite de la proteine tyrosine phosphatase 1b dans le systeme nerveux central
EP2004166A2 (fr) * 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibiteurs d'adhérence médiée par l'amine oxydase sensible aux semi-carbazides (ssao) et la vap-1 utilisés dans le traitement et la prévention de maladies
KR101567608B1 (ko) * 2007-02-08 2015-11-09 신타 파마슈티칼스 코프. 암과 같은 증식성 질환의 치료에 유용한 트라이아졸 화합물
EP2323737A2 (fr) * 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Composés de triazole qui modulent l'activité hsp90
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
WO2010040274A1 (fr) 2008-10-10 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 Nouveaux ligands de récepteurs d3 de la dopamine, leurs procédés de préparation et leurs applications
US9326955B2 (en) * 2008-10-31 2016-05-03 Loyola University Chicago Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions
EP2516446B1 (fr) * 2009-12-22 2014-08-13 Cephalon, Inc. Dérivés tricycliques et leur utilisation pharmaceutique et compositions
US9035059B2 (en) * 2011-03-14 2015-05-19 Taisho Pharmaceutical Co., Ltd. Nitrogen-containing condensed heterocyclic compound
BR112014026828A2 (pt) * 2012-05-30 2017-06-27 Hoffmann La Roche compostos de triazolo como inibidores de pde10
RU2561063C1 (ru) * 2014-07-01 2015-08-20 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Способ коррекции неврологических нарушений при хронической алкогольной интоксикации
EP3189041B1 (fr) 2014-09-03 2021-04-28 Ctxt Pty Ltd Derives de la tetrahydroisoquinoline en tant qu'inhibiteurs de la prmt5
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
EP3189048B1 (fr) 2014-09-03 2021-03-17 Ctxt Pty Ltd Inhibiteurs de la prmt5 derives du aminoindane, aminotetrahydronapthalene et l'aminobenzocyclobutane.
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
WO2018209267A2 (fr) * 2017-05-12 2018-11-15 Board Of Trustees Of The Southern Illinois University On Behalf Of Southern Illinois University Edwardsville 1,2,4-triazoles 3,4,5-trisubstitués et 3-thio-1,2,4-triazoles 3,4,5-trisubstitués et leurs utilisations
US10941153B2 (en) * 2018-05-31 2021-03-09 Regents Of The University Of Minnesota Substituted phenethylamine derivatives
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4408049A (en) 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4338453A (en) 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
FR2601952B1 (fr) * 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
AU644500B2 (en) * 1990-12-20 1993-12-09 Merrell Dow Pharmaceuticals Inc. 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
ES2103374T3 (es) 1991-05-20 1997-09-16 Upjohn Co Derivados de carboxamido-(1,2n)-carbociclo-2-aminotetralina.
DK0612244T3 (da) 1991-11-05 2002-01-14 Smithkline Beecham Corp Endothelinreceptorantagonister
FR2687146B1 (fr) 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
PT699069E (pt) 1993-04-27 2002-07-31 Smithkline Beecham Corp Antagonistas dos receptores de endotelina
DE4338396A1 (de) * 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
FR2722194B1 (fr) 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
JP2941950B2 (ja) * 1994-11-23 1999-08-30 ニューロゲン コーポレイション 或る種の４−アミノメチル−２−置換イミダゾール誘導体および２−アミノメチル−４−置換イミダゾール誘導体；新規な種類のドーパミン リセプタ亜型特異性リガンド
EP0817767B1 (fr) 1995-03-27 2000-05-24 Smithkline Beecham Plc Derives amines bicycliques et leur utilisation comme agents neuroleptiques
AU5272296A (en) * 1995-04-06 1996-10-23 Novo Nordisk A/S Benzopyranopyrrole compounds, their preparation and use
GB9518572D0 (en) 1995-09-12 1995-11-15 Smithkline Beecham Plc Compounds
AU7490496A (en) 1995-11-10 1997-05-29 Novo Nordisk A/S Enantiomers of cis-benz{e}indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
FR2742149B1 (fr) 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
DE69719191T2 (de) 1996-05-11 2003-11-27 Smithkline Beecham Plc Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren
SK282725B6 (sk) * 1996-05-31 2002-11-06 Pharmacia & Upjohn Company Arylom substituované cyklické amíny ako selektívne D3 ligandy dopamínu
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
ES2154470T3 (es) * 1996-08-14 2001-04-01 Smithkline Beecham Plc Derivados de tetrahidroisoquinolina y su uso farmaceutico.
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
AU735764B2 (en) 1996-12-06 2001-07-12 Abbott Laboratories Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds
FR2760014B1 (fr) * 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9708694D0 (en) * 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
IL132631A0 (en) 1997-05-03 2001-03-19 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9709303D0 (en) 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710366D0 (en) * 1997-05-20 1997-07-16 Biocompatibles Ltd Stent deployment device
FR2764890B1 (fr) 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
CZ20012551A3 (cs) 2002-03-13
CA2359952A1 (fr) 2000-07-20
KR20010086471A (ko) 2001-09-12
CN1345319A (zh) 2002-04-17
EP1140908B1 (fr) 2009-03-04
HK1045311A1 (en) 2002-11-22
ATE424398T1 (de) 2009-03-15
EP1140907B1 (fr) 2007-07-11
CN1267430C (zh) 2006-08-02
TR200102025T2 (tr) 2002-05-21
BG105783A (en) 2002-03-29
JP4933694B2 (ja) 2012-05-16
IL144136A0 (en) 2002-05-23
CN1149209C (zh) 2004-05-12
CO5150227A1 (es) 2002-04-29
CN1345318A (zh) 2002-04-17
ID29552A (id) 2001-09-06
PL349841A1 (en) 2002-09-23
AU773047B2 (en) 2004-05-13
CN1347414A (zh) 2002-05-01
DE50015802D1 (de) 2010-01-07
BR0007504A (pt) 2001-10-02
WO2000042038A1 (fr) 2000-07-20
WO2000042037A1 (fr) 2000-07-20
JP4615125B2 (ja) 2011-01-19
AU2541200A (en) 2000-08-01
AU2436700A (en) 2000-08-01
JP2002534521A (ja) 2002-10-15
US6579892B1 (en) 2003-06-17
PL200238B1 (pl) 2008-12-31
US6602867B1 (en) 2003-08-05
ES2334326T3 (es) 2010-03-09
CZ303926B6 (cs) 2013-06-26
EP1144405A1 (fr) 2001-10-17
WO2000042036A1 (fr) 2000-07-20
DE50014472D1 (de) 2007-08-23
BG105784A (en) 2002-02-28
CO5150182A1 (es) 2002-04-29
CO5150224A1 (es) 2002-04-29
HK1045311B (zh) 2007-03-30
CZ20012550A3 (cs) 2002-02-13
HUP0200522A2 (en) 2002-06-29
PL350246A1 (en) 2002-12-02
CA2359942A1 (fr) 2000-07-20
AR022229A1 (es) 2002-09-04
AR022228A1 (es) 2002-09-04
IL144136A (en) 2006-12-10
JP2002534520A (ja) 2002-10-15
KR100730667B1 (ko) 2007-06-21
IL144137A0 (en) 2002-05-23
AU2289700A (en) 2000-08-01
KR20010086470A (ko) 2001-09-12
EP1140907A1 (fr) 2001-10-10
ES2288839T3 (es) 2008-02-01
NZ512864A (en) 2003-04-29
EP1144405B1 (fr) 2009-11-25
ATE366729T1 (de) 2007-08-15
KR100687682B1 (ko) 2007-02-28
CA2359948A1 (fr) 2000-07-20
NO20013444L (no) 2001-07-11
US6583166B1 (en) 2003-06-24
BG65086B1 (bg) 2007-02-28
HUP0200709A2 (hu) 2002-07-29
KR100775720B1 (ko) 2007-11-09
ID29930A (id) 2001-10-25
ZA200106585B (en) 2002-08-12
TR200102026T2 (tr) 2001-12-21
KR20070032830A (ko) 2007-03-22
SK9862001A3 (en) 2002-04-04
ATE449768T1 (de) 2009-12-15
BG65105B1 (bg) 2007-02-28
HUP0200522A3 (en) 2003-05-28
NO20013443L (no) 2001-07-12
JP2002534519A (ja) 2002-10-15
NO20013443D0 (no) 2001-07-11
BR0007500A (pt) 2001-10-23
DE50015576D1 (de) 2009-04-16
HUP0200709A3 (en) 2004-07-28
TWI274750B (en) 2007-03-01
CA2359948C (fr) 2010-09-21
EP1140908A1 (fr) 2001-10-10
NZ512830A (en) 2003-08-29
NO20013444D0 (no) 2001-07-11
PL201889B1 (pl) 2009-05-29
ZA200106584B (en) 2002-08-12
AR022230A1 (es) 2002-09-04
HRP20010590A2 (en) 2003-08-31
AU772948B2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
SK9852001A3 (en) Triazole compounds with dopamine-d3-receptor affinity
DE60132235T2 (de) Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
KR100441073B1 (ko) 치환된아자-및디아자시클로헵탄및시클로옥탄화합물및그의용도
AU2014288115B2 (en) P2X4 receptor antagonist
JP2017522346A (ja) ブロモドメインに対して活性な化合物
KR20010021538A (ko) 트리아졸 화합물 및 도파민-ｄ₃-리간드로서의 그의 용도
WO2006028284A1 (fr) Dérivé de morpholine
KR20050034732A (ko) 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산
CN101918395B (zh) 三唑联噁二唑衍生物
WO2005111003A1 (fr) Analogues d’amino-tétrazoles et méthodes d’utilisation
CN101248048A (zh) 吡唑基lxr调节剂
US7465744B2 (en) Triazole compounds and the therapeutic use thereof
AU709133B2 (en) Benzoxazepine derivatives, salts thereof, and drugs containing the same
KR101586714B1 (ko) 피라졸 화합물
MXPA01006840A (en) Triazole compounds with dopamine-d3-receptor affinity